Loading
A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., now recruiting.
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy is a phase 1 interventional study registered as NCT05276310 by ImmuneOncia Therapeutics Inc., with 86 participants planned, started 2022-06-02. Conditions recorded: Advanced Cancer. Interventions recorded: IMC-002.
Shares IMC-002, ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/